Comparable stake leader
Douglas K. Bratton
SEC ownership of Aquestive Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001398733.
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- AQST on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Douglas K. Bratton
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Douglas K. Bratton
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001398733
- Issuer location
- Warren, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Aquestive Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Douglas K. Bratton
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
13D/G row: Douglas K. Bratton
Showing 1-8 of 50 holder rows.
Quick read
Douglas K. Bratton leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Douglas K. Bratton's linked filing trail.
Comparable ownership
Top 5
Douglas K. Bratton
11%
BlackRock, Inc.
6.4%
RTW INVESTMENTS, LP
5.2%
Venrock Healthcare Capital Partne...
2.9%
STATE STREET CORP
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Douglas K. Bratton |
13D/G
3/4/5
BRATTON DOUGLAS K · 10%+ Owner
|
11%
|
$28,720,687
10,077,434 shares
|
$0 | 31 Dec 2024 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.4%
from 13D/G
|
$33,568,590
8,069,373 shares
|
— | 30 Jun 2026 |
| RTW INVESTMENTS, LP |
13D/G
|
5.2%
|
$34,937,500
6,250,000 shares
|
$0 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
2.9%
|
$7,494,890
2,629,786 shares
|
$0 | 31 Dec 2024 |
| STATE STREET CORP |
13F
Company
|
2.3%
|
$12,180,563
2,928,020 shares
|
— | 30 Jun 2026 |
| WASATCH ADVISORS LP |
13F
Company
|
1.1%
|
$5,765,107
1,385,843 shares
|
— | 30 Jun 2026 |
| Janney Montgomery Scott LLC |
13F
Company
|
0.89%
|
$4,602,000
1,106,160 shares
|
— | 30 Jun 2026 |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
Company
|
0.84%
|
$4,352,090
1,046,175 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$3,708,818.
Buys
$0
Insiders: 0
Sells
$3,708,818
Insiders: 9
Net
-$3,708,818
Shares: -755,717
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 755,717
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 75,000 | $0 | $329,594 | -$329,594 |
| 3-6 | 0 | 403,947 | $0 | $1,686,628 | -$1,686,628 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 276,770 | $0 | $1,692,596 | -$1,692,596 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to Aquestive Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Alexander Mark Schobel
Net 12M change
-$3,708,820
Latest report
15 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alexander Mark Schobel | Chief Innovation/Tech Officer | $4,804,243 | Mixed | 15 Mar 2024 | ||
| Daniel Barber | President and CEO | $2,443,272 | -$1,547,172 | -39% | Filing P/S | 15 Jul 2026 |
| Carl N. Kraus | Chief Medical Officer | $1,977,325 | -$141,904 | -6.7% | Filing P/S | 15 Oct 2025 |
| A. Ernest Toth Jr. | Chief Financial Officer | $1,176,359 | -$243,094 | -17% | Mixed | 05 May 2026 |
| Peter E. Boyd | Chief People Officer | $1,169,183 | -$336,914 | -22% | Mixed | 05 May 2026 |
| Melina Cioffi | SVP, Regulatory Affairs | $1,133,780 | -$105,623 | -8.5% | Mixed | 15 May 2026 |
| Douglas K. Bratton | 10%+ Owner | $1,033,452 | Mixed | 02 Dec 2024 | ||
| Sherry Korczynski | Chief Commercial Officer | $989,372 | -$65,687 | -6.2% | Mixed | 08 Jun 2026 |
| Lori J. Braender | Corporate Secretary | $958,824 | -$167,346 | -15% | Mixed | 07 May 2026 |
| Stephen Wargacki | Chief Science Officer | $872,622 | Mixed | 07 Mar 2025 | ||
| Cassie Jung | Chief Operating Officer | $847,620 | -$975,687 | -54% | Mixed | 05 May 2026 |
| John Cochran | Director | $556,086 | Mixed | 10 Jun 2026 | ||
| Gregory B. Brown | Director | $454,822 | Mixed | 10 Jun 2026 | ||
| Thomas A. Zalewski | Chief Legal Officer | $415,000 | Mixed | 18 May 2026 | ||
| Matthew W. Davis | Chief Development Officer | $382,000 | Mixed | 09 Mar 2026 | ||
| Matthew J. Greenhawt | Chief Medical Officer | $294,140 | Mixed | 09 Mar 2026 | ||
| Marco Taglietti | Director | $143,220 | Mixed | 10 Jun 2026 | ||
| Abigail L. Jenkins | Director | $143,220 | Mixed | 10 Jun 2026 | ||
| Timothy E. Morris | Director | $143,220 | Mixed | 10 Jun 2026 | ||
| Julie Krop | Director | $143,220 | -$125,393 | -47% | Mixed | 23 Jun 2026 |
Recent insider transactions for Aquestive Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel Barber | AQST | Common Stock | Sale | -3.23% | $81,509 | $4.00 | -20,369 | 610,574 | 16 Jul 2026 | Direct |
| Daniel Barber | AQST | Common Stock | Sale | -0.73% | $18,683 | $4.03 | -4,631 | 630,943 | 15 Jul 2026 | Direct |
| Julie Krop | AQST | Common Stock | Sale | -100% | $125,392 | $5.02 | -25,000 | 0 | 23 Jun 2026 | Direct |
| Julie Krop | AQST | Common Stock | Options Exercise | 25,000 | 25,000 | 23 Jun 2026 | Direct | |||
| Julie Krop | AQST | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -25,000 | 0 | 23 Jun 2026 | Direct | ||
| Daniel Barber | AQST | Common Stock | Sale | -3.78% | $104,010 | $4.16 | -25,000 | 635,574 | 15 Jun 2026 | Direct |
| Timothy E. Morris | AQST | Stock Option (right to purchase) | Award | 50,500 | 50,500 | 10 Jun 2026 | Direct | |||
| Julie Krop | AQST | Stock Option (Right to Purchase) | Award | 50,500 | 50,500 | 10 Jun 2026 | Direct | |||
| Abigail L. Jenkins | AQST | Non-Qualified Stock Option (right to buy) | Award | -50% | -50,500 | 50,500 | 10 Jun 2026 | Direct | ||
| John Cochran | AQST | Stock Option (Right to Purchase) | Award | 50,500 | 50,500 | 10 Jun 2026 | Direct | |||
| Gregory B. Brown | AQST | Stock Option (Right to Purchase) | Award | 50,500 | 50,500 | 10 Jun 2026 | Direct | |||
| Marco Taglietti | AQST | Stock Option (Right to Purchase) | Award | 50,500 | 50,500 | 10 Jun 2026 | Direct | |||
| Sherry Korczynski | AQST | Common Stock | Tax liability | -1.13% | -2,714 | 238,403 | 08 Jun 2026 | Direct | ||
| Thomas A. Zalewski | AQST | Common Stock | Award | 100,000 | 100,000 | 18 May 2026 | Direct | |||
| Thomas A. Zalewski | AQST | Non-Qualified Stock Option (right to buy) | Award | 75,000 | 75,000 | 18 May 2026 | Direct | |||
| Daniel Barber | AQST | Common Stock | Sale | -1.23% | $35,413 | $4.29 | -8,257 | 660,574 | 15 May 2026 | Direct |
| Melina Cioffi | AQST | Common Stock | Tax liability | -0.61% | -1,667 | 273,200 | 15 May 2026 | Direct | ||
| Lori J. Braender | AQST | Common Stock | Tax liability | -37% | -135,690 | 231,042 | 07 May 2026 | Direct | ||
| Peter E. Boyd | AQST | Common Stock | Tax liability | -16.8% | -56,778 | 281,731 | 05 May 2026 | Direct | ||
| Daniel Barber | AQST | Common Stock | Tax liability | -33.4% | -335,922 | 668,831 | 05 May 2026 | Direct | ||
| A. Ernest Toth Jr. | AQST | Common Stock | Tax liability | -24.6% | -92,652 | 283,460 | 05 May 2026 | Direct | ||
| Cassie Jung | AQST | Common Stock | Tax liability | -26.4% | -72,734 | 202,246 | 05 May 2026 | Direct | ||
| Lori J. Braender | AQST | Common Stock | Tax liability | -17.2% | -76,147 | 366,732 | 05 May 2026 | Direct | ||
| Peter E. Boyd | AQST | Common Stock | Sale | -8.09% | $124,414 | $4.17 | -29,814 | 338,509 | 10 Mar 2026 | Direct |
| Daniel Barber | AQST | Common Stock | Sale | -15.2% | $753,965 | $4.17 | -180,677 | 1,004,753 | 10 Mar 2026 | Direct |
| Lori J. Braender | AQST | Common Stock | Sale | -8.3% | $167,346 | $4.17 | -40,102 | 442,879 | 10 Mar 2026 | Direct |
| Melina Cioffi | AQST | Common Stock | Sale | -8.43% | $105,623 | $4.17 | -25,311 | 274,867 | 10 Mar 2026 | Direct |
| A. Ernest Toth Jr. | AQST | Common Stock | Sale | -13.4% | $243,094 | $4.17 | -58,254 | 376,112 | 10 Mar 2026 | Direct |
| Sherry Korczynski | AQST | Common Stock | Sale | -6.13% | $65,687 | $4.17 | -15,741 | 241,117 | 10 Mar 2026 | Direct |
| Cassie Jung | AQST | Common Stock | Sale | -14.3% | $191,086 | $4.17 | -45,791 | 274,980 | 10 Mar 2026 | Direct |
| Peter E. Boyd | AQST | Common Stock | Award | 27.8% | 80,000 | 368,323 | 09 Mar 2026 | Direct | ||
| Peter E. Boyd | AQST | Non-Qualified Stock Option (right to buy) | Award | 42,500 | 42,500 | 09 Mar 2026 | Direct | |||
| Daniel Barber | AQST | Common Stock | Award | 28.4% | 262,000 | 1,185,430 | 09 Mar 2026 | Direct | ||
| Daniel Barber | AQST | Non-Qualified Stock Option (right to buy) | Award | 523,000 | 523,000 | 09 Mar 2026 | Direct | |||
| Lori J. Braender | AQST | Common Stock | Award | 19.8% | 80,000 | 482,981 | 09 Mar 2026 | Direct | ||
| Lori J. Braender | AQST | Non-Qualified Stock Option (right to buy) | Award | 50,000 | 50,000 | 09 Mar 2026 | Direct | |||
| Melina Cioffi | AQST | Common Stock | Award | 50% | 100,000 | 300,178 | 09 Mar 2026 | Direct | ||
| Melina Cioffi | AQST | Non-Qualified Stock Option (right to buy) | Award | 75,000 | 75,000 | 09 Mar 2026 | Direct | |||
| A. Ernest Toth Jr. | AQST | Common Stock | Award | 28% | 95,000 | 434,366 | 09 Mar 2026 | Direct | ||
| A. Ernest Toth Jr. | AQST | Non-Qualified Stock Option (right to buy) | Award | 70,000 | 70,000 | 09 Mar 2026 | Direct | |||
| Sherry Korczynski | AQST | Common Stock | Award | 41.2% | 75,000 | 256,858 | 09 Mar 2026 | Direct | ||
| Sherry Korczynski | AQST | Non-Qualified Stock Option (right to buy) | Award | 42,500 | 42,500 | 09 Mar 2026 | Direct | |||
| Cassie Jung | AQST | Common Stock | Award | 33.2% | 80,000 | 320,771 | 09 Mar 2026 | Direct | ||
| Cassie Jung | AQST | Non-Qualified Stock Option (right to buy) | Award | 42,500 | 42,500 | 09 Mar 2026 | Direct | |||
| Matthew W. Davis | AQST | Common Stock | Award | 100% | 50,000 | 100,000 | 09 Mar 2026 | Direct | ||
| Matthew W. Davis | AQST | Non-Qualified Stock Option (right to buy) | Award | 50,000 | 50,000 | 09 Mar 2026 | Direct | |||
| Matthew J. Greenhawt | AQST | Common Stock | Award | 75,000 | 75,000 | 09 Mar 2026 | Direct | |||
| Matthew J. Greenhawt | AQST | Non-Qualified Stock Option (right to buy) | Award | 50,000 | 50,000 | 09 Mar 2026 | Direct | |||
| Peter E. Boyd | AQST | Common Stock | Award | 7.45% | 20,000 | 288,323 | 04 Dec 2025 | Direct | ||
| Melina Cioffi | AQST | Common Stock | Tax liability | -1.03% | -2,083 | 200,178 | 02 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.